{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:14:41Z","timestamp":1772165681211,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Forschungszentrum Borstel - Leibniz Lungenzentrum"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Following the initial description of\n                      <jats:italic>Mycobacterium florentinum<\/jats:italic>\n                      in 2005, very few clinical cases have been reported and the optimal antimicrobial treatment and clinical outcomes are uncertain. Amikacin liposome inhalation suspension (ALIS) has received approval for the treatment of\n                      <jats:italic>Mycobacterium avium\/intracellulare complex<\/jats:italic>\n                      (MAC) pulmonary disease. However, there is little experience with its use for infections caused by less common nontuberculous mycobacteria (NTM). Moreover, the awareness of uncommon adverse effects is still limited.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 69-year-old female patient suffering from nodular bronchiectatic\n                      <jats:italic>Mycobacterium florentinum<\/jats:italic>\n                      pulmonary disease was treated with azithromycin, ethambutol, and rifampicin, administered three times per week. After 13\u2009months, owing to treatment failure, the therapy was changed to ALIS, moxifloxacin, and clofazimine. This resulted in rapid and sustained culture conversion. Concurrently, the patient exhibited increased cough and sputum, which was consistent with a clinical diagnosis of aspergillosis, as confirmed by evidence of\n                      <jats:italic>Aspergillus fumigatus<\/jats:italic>\n                      in respiratory specimens and a significant increase in serum\n                      <jats:italic>Aspergillus<\/jats:italic>\n                      IgG antibody levels. Following a six-month course of antifungal therapy, a marked improvement in the patient\u2019s symptoms was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      As with MAC pulmonary disease, combination antimicrobial therapy including ALIS was successful in a patient affected by a difficult-to-treat pulmonary infection caused by\n                      <jats:italic>Mycobacterium florentinum,<\/jats:italic>\n                      a rare NTM pathogen. Combination antibiotic treatment including ALIS may also be considered for other difficult-to-treat, non-MAC NTM- pulmonary diseases. During treatment, patients should be monitored for the emergence of Aspergillus co-infection.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-12321-3","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T16:18:07Z","timestamp":1765988287000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mycobacterium florentinum pulmonary disease: a case report and review of the literature"],"prefix":"10.1186","volume":"26","author":[{"given":"Fabian","family":"Leo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silke","family":"Polsfuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Przewosnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Groh\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph","family":"Lange","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"3","key":"12321_CR1","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1099\/ijs.0.63485-0","volume":"55","author":"E Tortoli","year":"2005","unstructured":"Tortoli E, Rindi L, Goh KS, Katila ML, Mariottini A, Mattei R, et al. Mycobacterium florentinum sp. nov., isolated from humans. Int J Syst Evol Microbiol. 2005 May, 1;55(3):1101\u201306. https:\/\/doi.org\/10.1099\/ijs.0.63485-0","journal-title":"Int J Syst Evol Microbiol"},{"key":"12321_CR2","doi-asserted-by":"publisher","unstructured":"Suomalainen S, Koukila-K\u00e4hk\u00f6l\u00e4 P, Brander E, Katila ML, Piilonen A, Paulin L, et al. Pulmonary infection caused by an unusual, slowly growing nontuberculous mycobacterium. J Clin Microbiol. 2001;39(7). https:\/\/doi.org\/10.1128\/JCM.39.7.2668-2671.2001","DOI":"10.1128\/JCM.39.7.2668-2671.2001"},{"issue":"9","key":"12321_CR3","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.3201\/eid1609.100433","volume":"16","author":"SS Syed","year":"2010","unstructured":"Syed SS, Aderinboye O, Hanson KE, Spitzer ED. Acute cervical lymphadenitis caused by Mycobacterium florentinum. Emerg Infect Dis. 2010 Sep;16(9):1486\u201387. https:\/\/doi.org\/10.3201\/eid1609.100433","journal-title":"Emerg Infect Dis"},{"key":"12321_CR4","doi-asserted-by":"publisher","unstructured":"Nukui Y, Nakamura H, Ishioka H, Miyamoto H, Okamoto A, Kazumi Y, et al. Synovitis of the wrist caused by Mycobacterium florentinum. Infection. 2014 Apr, 22;42(2):437\u201340. https:\/\/doi.org\/10.1007\/s15010-013-0561-5","DOI":"10.1007\/s15010-013-0561-5"},{"issue":"5","key":"12321_CR5","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1086\/314727","volume":"179","author":"JL Burns","year":"1999","unstructured":"Burns JL, Van DJ, Shawar RM, Otto KL, Garber RL, Quan JM, et al. Effect of chronic intermittent administration of inhaled tobramycin on Respiratory microbial flora in patients with cystic fibrosis. J Infect Dis. 1999 May;179(5):1190\u201396. https:\/\/doi.org\/10.1086\/314727","journal-title":"J Infect Dis"},{"key":"12321_CR6","doi-asserted-by":"publisher","unstructured":"Blomquist A, Inghammar M, Al Shakirchi M, Ericson P, Krantz C, Svedberg M, et al. Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study. BMC Pulm Med. 2022 Dec, 1;22(1). https:\/\/doi.org\/10.1186\/s12890-022-02054-3","DOI":"10.1186\/s12890-022-02054-3"},{"issue":"5","key":"12321_CR7","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1159\/000381289","volume":"89","author":"L M\u00e1iz","year":"2015","unstructured":"M\u00e1iz L, Vendrell M, Olveira C, Gir\u00f3n R, Nieto R, Mart\u00ednez-Garc\u00eda M\u00c1. Prevalence and factors associated with isolation of aspergillus and candida from sputum in patients with non-cystic fibrosis bronchiectasis. Respiration. 2015 Jun, 1;89(5):396\u2013403. https:\/\/doi.org\/10.1159\/000381289","journal-title":"Respiration"},{"issue":"179","key":"12321_CR8","doi-asserted-by":"publisher","first-page":"106338","DOI":"10.1016\/j.rmed.2021.106338","volume":"1","author":"D Raats","year":"2021","unstructured":"Raats D, Aldhaheri SMS, Marras TK, Mehrabi M, Brode SK. Aspergillus isolation in nontuberculous mycobacterial pulmonary disease: associated with antimycobacterial treatment initiation but not response. Respir Med. 2021 Apr;1(179):106338. https:\/\/doi.org\/10.1016\/j.rmed.2021.106338","journal-title":"Respir Med"},{"issue":"11","key":"12321_CR9","doi-asserted-by":"publisher","first-page":"e0188716","DOI":"10.1371\/journal.pone.0188716","volume":"12","author":"BW Jhun","year":"2017","unstructured":"Jhun BW, Jung WJ, Hwang NY, Park HY, Jeon K, Kang ES, et al. Risk factors for the development of chronic pulmonary aspergillosis in patients with nontuberculous mycobacterial lung disease. PLoS One. 2017 Nov, 30;12(11):e0188716. https:\/\/doi.org\/10.1371\/journal.pone.0188716","journal-title":"PLoS One"},{"key":"12321_CR10","doi-asserted-by":"publisher","unstructured":"Denning DW, Cadranel J, Beigelman-Aubry C, Ader F, Chakrabarti A, Blot S, et al. Chronic pulmonary aspergillosis: rationale and clinical guidelines for diagnosis and management. Eur Respir J. 2016 Jan, 1;47(1):45\u201368. https:\/\/doi.org\/10.1183\/13993003.00583-2015","DOI":"10.1183\/13993003.00583-2015"},{"issue":"3","key":"12321_CR11","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","volume":"160","author":"DE Griffith","year":"2021","unstructured":"Griffith DE, Thomson R, Flume PA, Aksamit TR, Field SK, Addrizzo-Harris DJ, et al. Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease. Chest. 2021 Sep;160(3):831\u201342. https:\/\/doi.org\/10.1016\/j.chest.2021.03.070","journal-title":"Chest"},{"key":"12321_CR12","doi-asserted-by":"publisher","unstructured":"Gibson J, Baird T, Pandey S, Tolson C, Coulter C, Eather G, et al. The clinical significance of Mycobacterium triplex. Respir Med. 2019 Nov;159:105808. https:\/\/doi.org\/10.1016\/j.rmed.2019.105808","DOI":"10.1016\/j.rmed.2019.105808"},{"key":"12321_CR13","doi-asserted-by":"publisher","unstructured":"Daley CL, Iaccarino JM, Lange C, Cambau E, Wallace RJ, Andrejak C, et al. Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline. Eur Respir J. 2020 Jul, 7;56(1):2000535. https:\/\/doi.org\/10.1183\/13993003.00535-2020","DOI":"10.1183\/13993003.00535-2020"},{"key":"12321_CR14","doi-asserted-by":"publisher","unstructured":"Chiron R, Hoefsloot W, Van Ingen J, Marchandin H, Kremer L, Morisse-Pradier H, et al. Amikacin liposomal inhalation suspension in the treatment of Mycobacterium abscessus lung infection: a French Observational experience. Open Forum Infect Dis. 2022 Oct, 1;9(10). https:\/\/doi.org\/10.1093\/ofid\/ofac465","DOI":"10.1093\/ofid\/ofac465"},{"issue":"3","key":"12321_CR15","doi-asserted-by":"publisher","first-page":"1800170","DOI":"10.1183\/13993003.00170-2018","volume":"51","author":"van Ingen J","year":"2018","unstructured":"van Ingen J, Aksamit T, Andrejak C, B\u00f6ttger, Cambau E, Daley CL, et al. Treatment outcome definitions in nontuberculous mycobacterial pulmonary disease: an NTM-NET consensus statement. Eur Respir J. 2018 Mar, 22;51(3):1800170. https:\/\/doi.org\/10.1183\/13993003.00170-2018","journal-title":"Eur Respir J"},{"issue":"9","key":"12321_CR16","doi-asserted-by":"publisher","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","volume":"16","author":"J Zhang","year":"2018","unstructured":"Zhang J, Leifer F, Rose S, Chun DY, Thaisz J, Herr T, et al. Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages. Front Microbiol. 2018 May;16(9):915. https:\/\/doi.org\/10.3389\/fmicb.2018.00915","journal-title":"Front Microbiol"},{"issue":"12","key":"12321_CR17","doi-asserted-by":"publisher","first-page":"6324","DOI":"10.1128\/AAC.01505-12","volume":"56","author":"J Van Ingen","year":"2012","unstructured":"Van Ingen J, Totten SE, Helstrom NK, Heifets LB, Boeree MJ, Daley CL. In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease. Antimicrob Agents Chemother. 2012 Dec;56(12):6324\u201327. https:\/\/doi.org\/10.1128\/AAC.01505-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"11","key":"12321_CR18","doi-asserted-by":"publisher","first-page":"797","DOI":"10.5588\/ijtld.23.0215","volume":"27","author":"K Kumar","year":"2023","unstructured":"Kumar K, Loebinger MR. Concomitant or sequential pulmonary infection with non-tuberculous mycobacteria and Aspergillus. Int J Tuberc Lung Dis. 2023 Nov, 1;27(11):797\u2013802. https:\/\/doi.org\/10.5588\/ijtld.23.0215","journal-title":"Int J Tuberc Lung Dis"},{"issue":"2","key":"12321_CR19","doi-asserted-by":"publisher","first-page":"270","DOI":"10.3390\/microorganisms9020270","volume":"9","author":"K Fukushima","year":"2021","unstructured":"Fukushima K, Kida H. New\/Different look at the presence of Aspergillus in mycobacterial pulmonary diseases. Long-term retrospective cohort study. Microorganisms. 2021 Jan, 28;9(2):270. https:\/\/doi.org\/10.3390\/microorganisms9020270","journal-title":"Microorganisms"},{"issue":"1","key":"12321_CR20","doi-asserted-by":"publisher","first-page":"1900798","DOI":"10.1183\/13993003.00798-2019","volume":"55","author":"BW Jhun","year":"2020","unstructured":"Jhun BW, Moon SM, Jeon K, Kwon OJ, Yoo H, Carriere KC, et al. Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study. Eur Respir J. 2020 Jan;55(1):1900798. https:\/\/doi.org\/10.1183\/13993003.00798-2019","journal-title":"Eur Respir J"},{"key":"12321_CR21","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1111\/j.1749-6632.2012.06816.x","volume":"1272","author":"A Chrdle","year":"2012","unstructured":"Chrdle A, Mustakim S, Bright-Thomas RJ, Baxter CG, Felton T, Denning DW. Aspergillus bronchitis without significant immunocompromise. Ann N Y Acad Sci. 2012 Dec;1272:73\u201385. https:\/\/doi.org\/10.1111\/j.1749-6632.2012.06816.x","journal-title":"Ann N Y Acad Sci"},{"issue":"6","key":"12321_CR22","doi-asserted-by":"publisher","first-page":"2102950","DOI":"10.1183\/13993003.02950-2021","volume":"59","author":"E Van Braeckel","year":"2022","unstructured":"Van Braeckel E, Page I, Davidsen JR, Laursen CB, Agarwal R, Alastruey-Izquierdo A, et al. Treatment outcome definitions in chronic pulmonary aspergillosis: a CPAnet consensus statement. Eur Respir J. 2022 Jun;59(6):2102950. https:\/\/doi.org\/10.1183\/13993003.02950-2021","journal-title":"Eur Respir J"},{"issue":"7","key":"12321_CR23","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1513\/AnnalsATS.202008-925OC","volume":"18","author":"KL Winthrop","year":"2021","unstructured":"Winthrop KL, Flume PA, Thomson R, Mange KC, Yuen DW, Ciesielska M, et al. Amikacin liposome inhalation suspension for Mycobacterium avium complex lung disease: a 12-month Open-label extension clinical trial. Ann Am Thorac Soc. 2021 Jul;18(7):1147\u201357. https:\/\/doi.org\/10.1513\/AnnalsATS.202008-925OC","journal-title":"Ann Am Thorac Soc"},{"issue":"8","key":"12321_CR24","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.jiac.2023.04.013","volume":"29","author":"D Takao","year":"2023","unstructured":"Takao D, Takeda K, Takazono T, Ozasa M, Ito Y, Ashizawa N, et al. A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension. J Infect Chemother. 2023 Aug;29(8):806\u201308. https:\/\/doi.org\/10.1016\/j.jiac.2023.04.013","journal-title":"J Infect Chemother"},{"issue":"4","key":"12321_CR25","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.resinv.2024.04.003","volume":"62","author":"T Kaneko","year":"2024","unstructured":"Kaneko T, Otoshi R, Sekine A, Baba T, Yamada C, Haga S, et al. Drug-related pneumonitis caused by amikacin liposome inhalation suspension: one pathologically proven case and single-center experience. Respir Investig. 2024 Jul;62(4):513\u201316. https:\/\/doi.org\/10.1016\/j.resinv.2024.04.003","journal-title":"Respir Investig"},{"issue":"10","key":"12321_CR26","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.3390\/medicina60101620","volume":"60","author":"AA Loukeri","year":"2024","unstructured":"Loukeri AA, Papathanassiou E, Kavvada A, Kampolis CF, Pantazopoulos I, Moschos C, et al. Amikacin liposomal inhalation suspension for non-tuberculous mycobacteria lung infection: a Greek Observational study. Medicina (B Aires). 2024 Oct, 3;60(10):1620. https:\/\/doi.org\/10.3390\/medicina60101620","journal-title":"Medicina (B Aires)"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-12321-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-12321-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T10:50:01Z","timestamp":1768992601000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-12321-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["12321"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-12321-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7727745\/v1","asserted-by":"object"}]},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from the patient before writing this report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The patient gave her written consent to the publication of her personal and clinical details, including medical images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"C.L. is supported by the German Center of Infection Research. F.L. and C.L provided consultation service to\n                      Insmed\n                      , a biopharmaceutical company that produces liposomal amikacin inhalation suspension for the treatment of NTM pulmonary disease. F.L., S.P. and C.L. received speakers honoraria from this company, outside the scope of this work. A.S.P. and C.G. declare no competing financial or non-financial interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}